Physician profile
Don T Smith
NPI 1053329268
$3,780.60
in general payments reported to CMS, 2019-2025
32 companies · $530 in 2025
The $530 reported for 2025 was more than what 91% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $216 · 2021: $495 · 2022: $570 · 2023: $485 · 2024: $768 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,782.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $742.86 | 2019-2025 | General - Therapies, Superion Indirect Decompression System, Patient Trial Kit |
| Abbvie INC. | $525.35 | 2021-2025 | Ubrelvy |
| Scilex Pharmaceuticals INC. | $423.74 | 2019-2025 | Ztlido |
| Pfizer INC. | $299.09 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $289.67 | 2019-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.88 | 2021-2025 | Relistor |
| Almatica Pharma LLC | $179.34 | 2021-2023 | Gralise |
| Amgen INC. | $160.78 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $134.64 | 2019-2020 | |
| Lilly USA, LLC | $132.95 | 2019-2023 | Emgality, Reyvow |
| Novartis Pharmaceuticals Corporation | $74.85 | 2019-2020 | |
| Averitas Pharma INC. | $66.23 | 2025 | Qutenza |
| Redhill Biopharma INC. | $60.16 | 2020-2022 | |
| Eisai INC. | $53.51 | 2020-2021 | |
| Pacira Therapeutics, INC. | $44.12 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $43.80 | 2019-2022 | |
| Sentynl Therapeutics, INC. | $39.69 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $38.01 | 2021 | |
| Idorsia Pharmaceuticals US INC | $32.20 | 2023-2024 | Quviviq |
| Nalu Medical, INC. | $28.16 | 2022 | |
| Ibsa Pharma INC. | $28.02 | 2023-2024 | Tirosint, Licart, Tirosint |
| Astellas Pharma US INC | $23.48 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.16 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $19.79 | 2025 | |
| Allergan, INC. | $16.77 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.59 | 2019 | |
| Biodelivery Sciences International, INC. | $15.14 | 2019 | |
| Upsher-Smith Laboratories LLC | $14.67 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.37 | 2021 | |
| Alfasigma USA, INC. | $12.81 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $11.93 | 2020 | |
| Shionogi INC | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.